BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38058823)

  • 1.
    Huang K; Ding S; Chen K; Guo C; Wu M; Zhang R; Wang L; Fu Y; Xiao J; Liu X
    Am J Cancer Res; 2023; 13(11):5549-5558. PubMed ID: 38058823
    [No Abstract]   [Full Text] [Related]  

  • 2. KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.
    Ni C; Wang X; Liu S; Zhang J; Luo Z; Xu B
    Sci Rep; 2024 Apr; 14(1):8284. PubMed ID: 38594266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.
    Lin A; Zhang H; Hu X; Chen X; Wu G; Luo P; Zhang J
    Pharmacol Res; 2020 Sep; 159():105028. PubMed ID: 32569820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular characteristics of
    Huang ZY; Wen L; Ye LF; Lu YT; Pat Fong W; Zhang RJ; Wu SX; Chen ZG; Cai YY; Xu RH; Li YH; Du ZM; Wang DS
    Ther Adv Med Oncol; 2024; 16():17588359231220600. PubMed ID: 38205077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNF43 is associated with genomic features and clinical outcome in BRAF mutant colorectal cancer.
    Shang P; Lu J; Song F; Zhao Y; Hong W; He Y; Shen W; Geng L
    Front Oncol; 2023; 13():1119587. PubMed ID: 37409251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
    Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
    Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer.
    Matsumoto A; Shimada Y; Nakano M; Oyanagi H; Tajima Y; Nakano M; Kameyama H; Hirose Y; Ichikawa H; Nagahashi M; Nogami H; Maruyama S; Takii Y; Ling Y; Okuda S; Wakai T
    Oncol Rep; 2020 Jun; 43(6):1853-1862. PubMed ID: 32236609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exome sequencing revealed comparable frequencies of RNF43 and BRAF mutations in Middle Eastern colorectal cancer.
    Siraj AK; Bu R; Masoodi T; Parvathareddy SK; Iqbal K; Al-Haqawi W; Al-Dossari H; Azam S; Qadri Z; Annaiyappanaidu P; Al-Dayel F; Al-Kuraya KS
    Sci Rep; 2022 Jul; 12(1):13098. PubMed ID: 35907983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of SPEN Mutations as Predictive Biomarkers for Immunotherapy Response in Colorectal Cancer: Insights from a Retrospective Cohort Analysis.
    Dong Y; Ye S; Li H; Li J; Liu R; Zhu Y
    J Pers Med; 2024 Jan; 14(2):. PubMed ID: 38392565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High tumor mutation burden indicates better prognosis in colorectal cancer patients with
    Wang J; Song J; Liu Z; Zhang T; Liu Y
    Front Oncol; 2022; 12():1015308. PubMed ID: 36452508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer.
    Zhang Y; Lin A; Li Y; Ding W; Meng H; Luo P; Zhang J
    Front Cell Dev Biol; 2020; 8():608969. PubMed ID: 33363171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of RNF43 frameshift mutations that drive Wnt ligand- and R-spondin-dependent colon cancer.
    Yamamoto D; Oshima H; Wang D; Takeda H; Kita K; Lei X; Nakayama M; Murakami K; Ohama T; Takemura H; Toyota M; Suzuki H; Inaki N; Oshima M
    J Pathol; 2022 May; 257(1):39-52. PubMed ID: 35040131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors.
    Song Y; Huang J; Liang D; Hu Y; Mao B; Li Q; Sun H; Yang Y; Zhang J; Zhang H; Chen H; Liu H; Zhang S
    Front Oncol; 2020; 10():549777. PubMed ID: 33680909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent frameshift mutations in 2 mononucleotide repeats of RNF43 gene and its regional heterogeneity in gastric and colorectal cancers.
    Jo YS; Kim MS; Lee JH; Lee SH; An CH; Yoo NJ
    Hum Pathol; 2015 Nov; 46(11):1640-6. PubMed ID: 26297255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.
    Bond CE; McKeone DM; Kalimutho M; Bettington ML; Pearson SA; Dumenil TD; Wockner LF; Burge M; Leggett BA; Whitehall VL
    Oncotarget; 2016 Oct; 7(43):70589-70600. PubMed ID: 27661107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer.
    Seeber A; Battaglin F; Zimmer K; Kocher F; Baca Y; Xiu J; Spizzo G; Novotny-Diermayr V; Rieder D; Puccini A; Swensen J; Ellis M; Goldberg RM; Grothey A; Shields AF; Marshall JL; Weinberg BA; Sackstein PE; Lim KH; Tan GS; Nabhan C; Korn WM; Amann A; Trajanoski Z; Berger MD; Lou E; Wolf D; Lenz HJ
    Clin Cancer Res; 2022 May; 28(9):1863-1870. PubMed ID: 35254413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors.
    Lin Y; Luo S; Luo M; Lu X; Li Q; Xie M; Huang Y; Liao X; Zhang Y; Li Y; Liang R
    Mol Carcinog; 2023 Sep; 62(9):1271-1283. PubMed ID: 37232365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.